Study details
Enrolling now
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Corvus Pharmaceuticals, Inc.
NCT IDNCT07441395ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18+
Locations
1 site in CA
About this study
This Phase 2 study is testing Soquelitinib in people with atopic dermatitis. The primary outcome being measured is Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12.
Based on ClinicalTrials.gov records.
PhasePhase 2
DrugSoquelitinib
Primary goalPercent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
kinase inhibitor
Endpoints
Primary: Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
Secondary: Response of achieving ≥4-point decrease in Peak Pruritus-Numerical Rating Scale (PP-NRS) score at Week 12, Safety and tolerability
Body systems
Dermatology